INTRODUCTION
Multidrug resistance (MDR) represents a significant clinical barrier to the successful treatment of many human tumours with chemotherapy. Many neoplasms exhibit an MDR phenotype either before treatment (de no o) and\or after treatment (acquired) (reviewed in [1] [2] [3] [4] [5] ). Many mechanisms for MDR have been described, including the up-regulation of one or more membrane proteins to lower intracellular drug concentrations, changes in Phase I and Phase II metabolic pathways for activation\detoxification of drugs, changes in DNA repair response and changes in apoptotic responses to toxic insult. One of the most common and well-described contributors to the MDR phenotype is the overexpression of P-glycoprotein (Pgp), which is a transmembrane ATP-dependent drug translocation protein [1] [2] [3] [4] [5] . The specific biophysical mechanism by which Pgp lowers the intracellular concentrations of drugs remains controversial. However, it is clear that the overexpression of Pgp is associated with a clinical MDR phenotype and a poor prognosis for many human cancers [2, [5] [6] [7] [8] [9] .
Pgp is a member of the ATP-binding cassette (ABC) transmembrane protein family, which includes : the MDR-associated protein (' MRP '), whose overexpression is also associated with multidrug resistance [10] ; the cystic fibrosis transmembrane conductance regulator protein (CFTR), mutations of which cause cystic fibrosis [11] ; and the sulphonylurea receptor (' SUR ') [12] . Pgp is expressed in a variety of normal tissues, including liver, kidney and colon ; not surprisingly, tumours arising from these tissues usually overexpress Pgp as part of their MDR phenotype [9, [13] [14] [15] . However, Pgp can also be overexpressed in Abbreviations used : ABC, ATP-binding cassette ; CFTR, cystic fibrosis transmembrane conductance regulator ; GFP, green fluorescent protein ; MDCK, Madin-Darby canine kidney ; MDR, multidrug resistance ; MMC, mitomycin C ; Pgp, P-glycoprotein. 1 These authors contributed equally to this work. 2 Present address : Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853-6401, U.S.A. 3 To whom correspondence should be addressed (e-mail josh.hamilton!dartmouth.edu).
be suppressed. This was followed by a rapid and sustained decrease in cell-surface expression at later times, presumably as a consequence of the initial decrease in mRNA expression. These studies imply that there are at least two independent chemosensitive steps that can alter Pgp biogenesis : one at the level of mRNA transcription and the other at the level of Pgp trafficking.
Understanding the combined consequences of these two mechanisms might lead to novel chemotherapeutic approaches to overcoming drug resistance in human cancers by altering either Pgp mRNA expression or trafficking to the membrane.
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tumours from tissues that do not normally express, such as breast [14, 16] . The mechanism of Pgp up-regulation in tumours in i o is still unclear, but it can occur de no o as in acute myelogenous leukaemia [6, 15] or can be acquired over the course of cancer treatment as in breast and ovarian cancer [8, 15, 16] . Previous work by several laboratories has demonstrated that MDR1 gene transcription and MDR1 mRNA expression can be induced by certain DNA-damaging agents, including chemotherapeutic drugs such as doxorubicin, simple alkylating agents such as methyl methanesulphonate, and genotoxic chemical carcinogens that induce bulky DNA adducts, such as aflatoxin B " and 2-acetylaminofluorene [17] [18] [19] [20] [21] [22] . In contrast, our laboratory has recently shown that Pgp mRNA and overall protein expression can be significantly suppressed by treatment with DNA cross-linking agents, including the cancer chemotherapy drugs mitomycin C (MMC), cisplatin, carboplatin and BMS181174, and the carcinogen chromium(VI) [12] . We are currently examining the mechanistic basis for this suppression and its possible utility as part of a combination cancer chemotherapy regimen ; however, the principal mechanism for the suppression seems to be a down-regulation of MDR1 gene transcription occurring immediately after treatment with drug. We have hypothesized that this is primarily a gene-selective nuclear response to the DNA cross-links that are formed by these agents [12, [23] [24] [25] .
However, preliminary results from our laboratory also suggested that immediately after treatment with MMC there was a transient increase in membrane-associated Pgp during a period when there was no net increase in total cellular Pgp and when mRNA levels were actually decreasing. On the basis of these observations we postulated that there might be a second point of Pgp regulation that mediates changes in Pgp trafficking from an intracellular pool to the cell surface in direct response to a toxic chemical challenge. The purpose of these studies was to test this hypothesis in detail. As one way of examining this, we developed a genetic construct expressing a green fluorescent protein (GFP)-tagged human Pgp protein under the transcriptional control of the human MDR1 promoter. We used this construct to generate stably transfected cell lines in the Madin-Darby canine kidney (MDCK)-C7 parental line. These cell lines were used to investigate the effects of MMC on the expression of GFP-Pgp. These studies demonstrate that this stably transfected GFP-Pgp is fully functional and is expressed in a similar manner to native Pgp, and that doxorubicin and MMC have differential effects on Pgp expression. Our results suggest that there are at least two independent levels of chemosensitive regulation of Pgp expression. The first has previously been well described and is at the level of MDR1 mRNA transcriptional expression. The second is at a post-transcriptional and post-translational level which probably involves trafficking of functional Pgp to the plasma membrane, resulting in a net movement of Pgp from a cytoplasmic pool to the cell surface in response to treatment with drug.
EXPERIMENTAL

Cell culture and treatments
H4IIE rat hepatoma cells were cultured as described previously [12] . MDCK-C7 cells were a gift from Dr Hans Oberleithner (Wurzburg, Germany). Cells were grown in minimal essential medium (Gibco BRL, Gaithersburg, MD, U.S.A.) supplemented with 10 % fetal bovine serum (Hyclone, Logan, UT, U.S.A.), 50 units\ml penicillin (Sigma Chemical Co., St Louis, MO, U.S.A.), 50 µg\ml streptomycin (Sigma) and 2 mM -glutamine (Gibco BRL). The cells were incubated at 37 mC with air\CO # (19 : 1), provided with fresh medium every 2 days and passaged once a week. Treatments were performed in serum-free medium for 4 h unless otherwise stated. Control cells were treated with solvent alone in serum-free medium. After treatment, completed medium was added back to the cells for time points longer than 4 h.
Cloning
The human MDR promoter (hMDRpro, k996 to j44) [22] The GFP expression vector pEGFP-C1 (Clontech, Palo Alto, CA, U.S.A.) was digested with Ase1 and Nhe1 ; the cytomegalovirus promoter was excised. pCR 3.1\human MDR (hMDR) promoter was also digested with Ase1 and Nhe1 and the hMDR promoter was ligated into the pEGFP-C1 vector in place of the cytomegalovirus promoter to generate hMDRpro\ pEGFP-C1.
The human MDR gene 1 cDNA (hMDR1) was a generous gift from Dr William Skach (Oregon Health Science Center, Portland, OR, U.S.A.), originally from Dr. M. M. Gottesman (National Cancer Institute, Bethesda, MD, U.S.A.). Owing to a limited number of restriction sites, the cDNA for hMDR1 was subcloned in two steps. First, the construct hMDRpro\pEGFP-C1 was digested with BglII, treated with Klenow enzyme, then digested with EcoRI. hMDR1 was digested with BstUI and EcoRI, and the resulting 1100 bp piece of the hMDR1 cDNA (EcoRI, BstUI) was ligated into the hMDRpro\pEGFP-C1 vector to generate hMDRpro\pEGFP-C1\hMDR1-1100 bp. Secondly, hMDRpro\pEGFP-C1\hMDR1-1100 bp was digested with EcoRI\SmaI, and MDR1 was digested with EcoRI\PmeI. The 3300 bp fragment of the hMDR1 cDNA (EcoRI, PmeI) was ligated to the hMDRpro\pEGFP-C1\hMDR1-1100 bp fragment to yield hMDRpro\pEGFP-C1\hMDR1. All ligation sites were sequenced to verify the correct reading frame.
Stable transfections
MDCK-C7 cells were plated at 600 000 cells per T75 flask (Corning, Acton, MA, U.S.A.) ; 24 h after plating, cells were transfected with MDR-GFP DNA in PFx-2 PerFect lipid (Invitrogen) in Opti-MEM medium (Gibco BRL) without any supplements, in accordance with the manufacturer's protocol, with a lipid-to-cDNA ratio of 3 : 1. After 8 h the DNA\lipid mixture was removed and replaced with completed medium. At 12 h after transfection, 0.3 mg\ml G418 (Gibco BRL) was added to the medium to select for cells expressing the hMDRpro\ pEGFP\hMDR1 construct. At 2 weeks after transfection, GFPpositive cells were sorted into 96-well plates (Falcon ; Becton Dickinson, Franklin Lakes, NJ, U.S.A.) at a density of one cell per well by a FACStar Plus cell sorter (Becton Dickinson, San Jose, CA, U.S.A.). Cells were clonally expanded, and three clones designated MDR4, MDR10, MDR29 were selected on the basis of bright green fluorescence as detected by a fluorescence microscope (Axiophot ; Zeiss) equipped with a halogen lamp and a FITC filter set. These clones were characterized further in detail.
Western blot analysis
Cells were grown to 70 % confluence on six-well plates. After treatment with drug, cells were lysed and total or plasma membrane proteins were collected as follows. For total proteins, cells were lysed in 50 mM Tris\HCl (pH 8.0)\150 mM NaCl\1 % (v\v) Nonidet P40 containing a protease inhibitor cocktail (Complete Mini ; Roche Diagnostic Corp., Indianapolis, IN, U.S.A.) on ice. Detergent-insoluble materials were removed by centrifugation at 12 000 g for 10 min. Plasma membrane fractions were purified as described previously [26] . Cells were overlaid for 10 min at room temperature with 20 mM Tris\HCl (pH 7.4)\2 mM EDTA\1 mM EGTA\0.1 % digitonin (Sigma) containing protease inhibitors, as described above. Cells were scraped, homogenized and centrifuged at 12 000 g for 10 min. The supernatant containing the cytosolic fraction was removed from each sample. The crude plasma membrane proteins were solubilized in the Nonidet P40 buffer described above. SDS\ PAGE was performed under reducing conditions on 4-15 % (w\v) minigels with 10 µg of protein lysate per lane. Proteins were separated and transferred to PVDF membrane (Millipore, Bedford, MA, U.S.A.) in Towbin's transfer buffer [25 mM Tris\HCl\192 mM glycine\12 % (v\v) methanol]. After transfer, the blots were blocked and probed sequentially, first with C219 (Centocor, Malvern, PA, U.S.A.) or F4 (Neomarkers, San Diego, CA, U.S.A.) overnight at 4 mC and then with a horseradish-peroxidase-labelled anti-mouse IgG secondary antibody (Amersham, Piscataway, NJ, U.S.A.). Membranes were washed six times in PBST [PBS\0.3 % (v\v) Tween 20] at room temperature for 10 min each between probings. The blots were developed with enhanced chemiluminescence substrate (Pierce) and exposed to film. For GFP detection, blots were probed with an anti-GFP antibody (Clontech). Digital densitometry was performed as described previously [12] .
Accumulation of daunorubicin
To assess Pgp function, cellular accumulation of the fluorescent Pgp substrate drug, daunorubicin, was assayed by flow cytometry. Cells were seeded at 70 % confluence and treated for 24 h with 20 µM verapamil (Sigma) for 1.5 h to block the transport of daunorubicin. After treatment with verapamil, all flasks were treated with 1 µM daunorubicin (Calbiochem, San Diego, CA, U.S.A.) for 1 h. After the 1 h daunorubicin treatment, the T25 flasks were washed with PBS (without Ca# + or Mg# + ) and the cells were trypsinized (Trypsin EDTA ; Gibco BRL), removed from the flask, pelleted by centrifugation, resuspended in PBS (containing Ca# + and Mg# + ) and immediately analysed by FACScan (Becton Dickinson). For each sample 10 000 cells were analysed for GFP (green, excitation at 488 nm, emission at 507 nm) and daunorubicin (red, 488 nm\575 nm) fluorescence. Data analysis was performed with CellQuest (Becton Dickinson) software.
Flow cytometric detection of GFP and Pgp expression
Evaluation of Pgp expression in flow cytometric studies of the MDCK\MDR29 cell line was determined with a high-affinity Pgp monoclonal antibody that recognizes an external epitope of the protein [27] conjugated with phycoerythrin with an F\P ratio of 1.0 (Becton Dickinson). Antigen-saturating protein concentrations of the primary and isotype-matched, PE-conjugated, control antibody (Pharmingen) were incubated for 30 min at 20 mC with 250 000 cells from each sample per 50 µl in PBS with 0.1 % sodium azide in accordance with the manufacturer's recommendations. Cells were washed, pelleted, resuspended in 500 µl and fixed with 1 % (w\v) paraformaldehyde and analysed immediately. Ten thousand events were collected per sample in list-mode files during laser excitation in the FACScan Analyzer with LYSIS II software (Becton Dickinson) for each experiment. Identical detection settings were used for all studies. Data were processed with CellQuest software (Becton Dickinson).
All studies were conducted in triplicate with sham-treated controls corresponding to each time point. Time-course evaluations of Pgp and GFP expression were conducted with non-cytotoxic doses of MMC and doxorubicin as defined below.
Cells were plated in T25 flasks (Falcon) to ensure 30-70 % confluence during the time-course studies (96 h). Viability in selected samples throughout the time-course studies was determined by the addition of 7-aminoactinomycin D (Viaprobe4 ; Pharmingen). Pgp and GFP expression in non-viable cell populations were excluded. The median fluorescence of the primary Pgp antibody was corrected for non-specific antibody fluorescence in both the drug-treated and sham-treated samples. Pgp and GFP fluorescence were normalized relative to pretreatment values.
Cytotoxicity assay
Cells were plated in 96-well plates (Fisher, Medford, MA, U.S.A.) at a density of 1000 cells per well ; 24 h after plating, the cells were dosed with 0-10 µM doxorubicin in serum-free medium as described above. The cells were incubated for 3 days and assayed with the CellTiter 96 AQueous One Solution Reagent (Promega) in accordance with the manufacturer's instructions. The data were collected and analysed with Softmax software. A cytotoxicity assay was also performed with cisplatin (0-30 µM) as described above.
Statistics
Statistical analysis was performed with InStat for Macintosh software (version 2.0b ; GraphPad Software, San Diego, CA, U.S.A.).
RESULTS
Our previous studies on the effects of MMC on Pgp mRNA and protein expression had demonstrated an overall suppression of MDR1 mRNA and total cellular Pgp levels in several rat and human cell lines [12] . However, in the present study we reexamined this phenomenon at a more detailed level initially in the rat hepatoma H4IIE cells (Figure 1 ), comparing levels of
Figure 1 Differential effects of MMC on total cellular and membraneassociated Pgp levels
Rat hepatoma H4IIE cells were cultured and treated with 0.1 µM MMC for 4 h as described previously [12] . Western analysis of Pgp levels was performed with 50 µg per sample of either total cellular protein ($) or membrane protein fraction () extracts from treated cells by using the C219 monoclonal antibody as described previously [12] and in the Experimental section. Images were scanned digitally and quantified by digital densitometry as described previously and in the Materials and methods section. total and plasma-membrane-associated Pgp. We observed a transient approx. 2-fold increase in membrane-associated Pgp within the first 24 h after treatment with MMC, during a period when total cellular Pgp levels were unchanged (Figure 1 ). At subsequent time points there was a parallel decrease in both total and membrane Pgp to levels well below control ; this seemed to be a consequence of the significant decrease in MDR1 mRNA levels previously observed within the first 24 h after treatment with MMC [12] . This suggested that MMC, and perhaps other drugs, might be simultaneously affecting both MDR1 gene expression and the cellular localization of Pgp protein.
To assess the effects of drugs on membrane Pgp protein expression more directly, we developed a cDNA construct expressing a GFP-tagged human Pgp protein under the control of the human MDR1 promoter region (see the Experimental section). This construct was stably transfected into MDCK-C7 cells. Single cells expressing GFP were isolated by FACS, independent cell lines were established by subcloning and these lines were then characterized for GFP-Pgp expression. As shown in Figure 2(A) , three different cell lines, designated MDR4, MDR10 and MDR29, expressed a protein that was detectable by Western blotting with an anti-Pgp antibody, which migrated at a position equivalent to the higher predicted size of the hybrid protein (approx. 210 kDa, consisting of 180 kDa Pgp plus 27 kDa GFP) and was not detected in the C7 parental line. An anti-GFP antibody recognized this higher-molecular-mass band in the three transfected cell lines but not in the parental line (Figure (Figure 2A ).
Daunorubicin accumulation, as measured by flow cytometry, was then used to assess functional Pgp in each cell line. Daunorubicin is a fluorescent Pgp substrate ; cellular accumulation of this drug has been shown to be a sensitive and accurate measure of functional Pgp in cells. As shown in Figure 3 , the three MDR cell lines demonstrated significantly less daunorubicin accumulation than did the parental cell line. These results suggested that these cell lines were expressing the GFP-Pgp protein in a functional form on the cell surface, such that their total Pgp levels were greater than that of the parental cell line. In addition, treatment of the cells with the Pgp inhibitor verapamil increased daunorubicin levels in both the parental and MDR cell lines, although drug accumulation in the presence of verapamil was less in the MDR cell lines than in the parental line. However, because verapamil does not fully block Pgp function, this is also consistent with the higher level of functional GFP-Pgp protein on the cell surface of the transfected cells than in the parental cell line.
Cytotoxicity assays also confirmed an increase in functional expression of Pgp in the transfected cells. As shown in Table 1 , the EC &! for cytotoxicity (colony formation) by the Pgp substrate drug, doxorubicin, was approx. 2.5-3.5-fold greater in the MDR cell lines than in the parental cell line, whereas the EC &! values for cytotoxicity by the non-Pgp substrate drug, cisplatin, were identical in all four cell lines. These results are consistent with the conclusion that these three MDR cell lines expressed full-length hybrid GFP-Pgp that was expressed on the cell surface in a form that was functionally similar to that of the native Pgp protein.
Table 1 Relative toxicity of doxorubicin and cisplatin in the parental and stably transfected MDCK cell lines
Cytotoxicity was measured by a colony-forming assay as described in [12] and in the Experimental section. Cytotoxicity dose-response curves were generated for each drug in each cell line by treating triplicate cultures for each concentration (4 h) over a 100-fold range of doses (results not shown) ; the EC 50 for cytotoxicity was calculated from each curve by using the standard dose-response curve-fitting equations of Prism statistical software (version 2.0b ; Graphpad Software). 
Figure 4 Effects of MMC on plasma-membrane GFP-Pgp expression in MDR29 cells
Cells were treated with 0.1 µM MMC for 4 h and analysed for GFP-Pgp levels. Western blotting of membrane protein samples (10 µg per sample) was performed as described in the Experimental section and in the legends to Figures 1 and 2 above with the use of the F4 monoclonal antibody. A representative blot is shown in the inset (note that there was no change in apparent mobility as determined by standards ; the apparent upward shift across this gel was a result of a ' smile '). Densitometric analysis of similar blots for each set of samples was performed as described in [12] Subsequent experiments were performed with the MDR29 cell line, because this was the highest expresser of the GFP-Pgp protein.
MDR29 cells were treated with a single non-cytotoxic dose of MMC ; GFP-Pgp protein expression was measured by two different approaches. As shown in Figure 4 , MMC treatment caused a doubling of GFP-Pgp levels at 6 h as detected by Western blotting in plasma-membrane-enriched preparations. Measurement of Pgp by flow cytometry with an antibody against an extracellular epitope demonstrated no effect at 6 h, but a doubling in cell surface Pgp at 12 h after MMC treatment. Pgp levels as detected by both methods decreased subsequently to approximately half that of controls by 24 h after MMC and remained low until the end of the time course, 72 h after MMC treatment (Figure 4) . Thus the basic response of GFP-Pgp to MMC in these cells was similar to that observed previously for native Pgp in H4IIE (Figure 1 ) and other cell lines, although the overall time course for this phenomenon was more rapid in the MDR29 cells. This seems to be a cell-type-specific phenomenon in which the kinetics of Pgp biogenesis is slightly different in each cell line. The temporal discrepancy between the Western and flow cytometry Pgp measurements suggests that there was a net movement of Pgp towards the plasma membrane by 6 h but that Pgp had not been fully inserted into the membrane in a functional orientation until 12 h after MMC treatment.
The functional consequences of these treatments were examined by measuring daunorubicin accumulation in MDR29 cells after treatment with MMC. As shown in Figure 5(A) , there was a significant decrease in daunorubicin accumulation in cells treated for 12 h with MMC ; drug levels in both control and MMC-treated cells were sensitive to verapamil, as predicted from the results in Figure 4 in which membrane Pgp levels had increased. Conversely, there was a verapamil-sensitive increase in drug accumulation at 48 h after MMC in treated compared with control cells (Figure 5B ), which is consistent with a MMCinduced decrease in functional cell-surface Pgp expression at 48 h, as shown in Figure 4 .
In contrast with the effects of MMC on Pgp expression, treatment of MDR29 cells with the anthracycline doxorubicin resulted in a progressive and substantial increase in membrane Pgp levels over a 24-72 h period after treatment ( Figure 6 ). Cellular GFP levels were increased earlier and to a greater extent than Pgp membrane levels after treatment with doxorubicin, indicating an initial increase in total cellular GFP-Pgp protein expression that was subsequently followed by an increase in plasma-membrane-associated GFP-Pgp. This is consistent with many previous reports demonstrating that treatment of Pgpexpressing cells with doxorubicin and other anthracyclines leads to an increase in MDR1 mRNA expression and Pgp protein expression [24] . As shown in Figure 7 , doxorubicin caused a significant decrease in daunorubicin accumulation in MDR29 cells at 48 h, as predicted by the increase in cell surface Pgp shown in Figure 6 . In summary, doxorubicin caused an increase in total cellular GFP-Pgp expression which led to an increase in functional membrane GFP-Pgp expression. In contrast, MMC caused an initial increase in functional membrane GFP-Pgp expression in the absence of increased total cellular GFPPgp expression, indicating a rapid and substantial increase in the net movement of GFP-Pgp to the cell surface in response to this drug.
DISCUSSION
Acquired drug resistance is a significant clinical issue in human cancers. In breast cancer, for example, newly diagnosed tumours that have not been pretreated with chemotherapy have little or no expression of Pgp and respond well to a variety of Pgp substrate drugs such as the anthracyclines and the taxanes [8, [14] [15] [16] . In fact, the largest study so far conducted reported no detectable Pgp expression in 248 consecutive samples [16] . However, after repeated rounds of chemotherapy with a Pgp substrate agent such as doxorubicin, expression of Pgp was detected in 62 % of all specimens examined [8, 12, 28] . The acquisition of a drug resistance phenotype is one of the primary reasons for the loss of responsiveness in late-stage tumours.
The MDR1 gene coding for Pgp is an inducible gene whose expression can be modulated by drugs, hormones and other stimuli [17] [18] [19] . For example, the rat mdr1 gene was demonstrated to be induced by treatment of rat hepatocytes with various DNA-damaging agents that form monoadducts, including simple alkylating agents such as methyl methanesulphonate, agents that form bulky monoadducts such as aflatoxin B " and 2-acetylaminofluorene, and with anthracyclines and their derivatives, such as doxorubicin and mitoxantrone [21, 22, 29] . It is important to note that, whereas cell lines selected for drug resistance in culture can overexpress Pgp by 50-100-fold or more, human cancers in i o typically overexpress Pgp and other MDR-associated proteins by 2-5-fold, which is sufficient to confer a drug resistance phenotype [3, 4] . Thus increases or decreases in the functional expression of Pgp of 2-5-fold in cell lines expressing Pgp at levels comparable with those of human MDR tumours would be expected to be directly clinically relevant.
We recently demonstrated that MMC treatment (0.1 µM for 4 h) of cancer cells that naturally overexpress Pgp at levels comparable with those in MDR cancers in i o led to a significant decrease in MDR1 mRNA and subsequent Pgp protein expression. Pgp protein levels were at their lowest between 48 and 84 h after a single MMC treatment before recovering to control levels. This suppression occurred in both rodent and human cell lines, in those derived from tumours of the breast, colon, kidney, liver and brain and from acute leukaemia, and in cells grown either as adherent monolayers or as non-adherent spheroid cultures [12] . The primary target for the suppression of Pgp expression by MMC and other DNA cross-linking agents seemed to be the transcription of the MDR1 gene ; we have hypothesized that this is a direct or indirect result of the formation of DNA cross-links by these agents at or near the MDR1 proximal promoter [12] . Similar effects of these agents on the transcription of another inducible gene, PEPCK (encoding phosphoenolpyruvate carboxykinase), were directly associated with specific regulatory elements within its promoter region [30, 31] .
In this study we have provided evidence for a second target for the effects of MMC on Pgp expression. This second step seems to involve the trafficking and\or maturation of nascent Pgp protein, because it does not involve a change in Pgp protein expression and because it results in a net movement of existing Pgp protein from an intracellular pool to the cell surface in response to treatment with MMC. Understanding the regulation of this step will be important in evaluating the overall MDR response of a tumour to chemotherapy. For MMC, a net movement of Pgp to the cell surface seems to be a futile response, because the dominant effect of this drug is to suppress Pgp mRNA expression, leading to an overall decrease in Pgp protein expression at later times after drug treatment. It is therefore the combined effects on these two independent pathways that dictates the overall effects of a given drug on Pgp expression in tumour cells.
This phenomenon might also provide clues about the regulation of other gene products in this protein family, such as the related membrane ABC protein, CFTR, mutations of which are responsible for cystic fibrosis. In the case of CFTR, the ∆F508 mutation, which is present in 67 % of all known CF patients, results in a decrease in expression of functional CFTR protein at the cell surface. This mutation is believed to result in a defect in CFTR folding and subsequent trafficking via the Golgi [32] [33] [34] . However, experimental cell culture procedures that aid in the folding and trafficking of this mutant to the cell surface also restore a normal phenotype [35] [36] [37] , indicating that the folded and membrane-inserted ∆F508-CFTR protein functions normally. There may be one or more common steps in trafficking of these ABC proteins that is drug sensitive. Interestingly, other experiments in our laboratory have demonstrated that both MMC and doxorubicin increase the functional cell-surface expression of CFTR and that doxorubicin increases the functional cell-surface expression of ∆F508-CFTR in epithelial cells. This seems to be primarily through a post-transcriptional mechanism involving the net movement of CFTR to the membrane [38] , suggesting a possible mechanism for reversing the ∆F508 phenotype by using systemic chemotherapy.
Our results suggest that MMC might be able to selectively increase one or more steps in post-transcriptional Pgp expression leading to functional membrane insertion. These might include changes in any step in the Pgp biosynthetic pathway. A recent study suggested that Pgp substrate drugs can act as ' chemical chaperones ' to increase the cell-surface expression of folding mutants of Pgp comparable to that of the ∆F508-CFTR folding mutant [39] . It remains to be determined whether such a mechanism is responsible for the effects that we have observed. However, it should be noted that MMC is not a substrate (or is only a very poor substrate) for Pgp, yet it seems to be highly effective at increasing the net movement of Pgp to the cell surface. Moreover, doxorubicin, a Pgp substrate, increased the overall expression of Pgp but did not seem to affect its net movement to the membrane. It might be that both phenomena are occurring, i.e. Pgp substrate drugs might selectively aid in the folding of mutant or misfolded Pgp proteins, whereas a larger class of cytotoxic drugs might (also) be able to increase the trafficking of Pgp to the cell surface. We hypothesize that this latter phenomenon is a specific acquired regulatory step, which serves as a protective response of cells to cytotoxic xenobiotic challenge. The precise mechanistic basis for these effects remains to be determined.
